NEW ORLEANS, Nov 12 (Reuters) - GlaxoSmithKline Plc’s (GSK.L: Quote, Profile, Research, Stock Buzz) diabetes medicine Avandia failed to significantly reduce progression of plaque buildup in coronary arteries in a clinical trial presented at a major heart meeting on Wednesday.
